Q3 EPS Estimates for Envoy Medical Lifted by Analyst

Envoy Medical, Inc. (NASDAQ:COCH) – Analysts at Brookline Capital Management boosted their Q3 2025 earnings per share (EPS) estimates for Envoy Medical in a research note issued on Thursday, October 9th. Brookline Capital Management analyst T. Bussian now forecasts that the company will post earnings of ($0.24) per share for the quarter, up from their prior forecast of ($0.30). The consensus estimate for Envoy Medical’s current full-year earnings is ($1.21) per share. Brookline Capital Management also issued estimates for Envoy Medical’s Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.13) EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Envoy Medical in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.50.

Envoy Medical Stock Up 1.5%

Shares of Envoy Medical stock opened at $0.90 on Monday. Envoy Medical has a 12 month low of $0.74 and a 12 month high of $3.09. The business has a fifty day simple moving average of $1.19 and a 200 day simple moving average of $1.38. The stock has a market cap of $21.39 million, a PE ratio of -0.63 and a beta of 2.09.

Envoy Medical (NASDAQ:COCH) last announced its quarterly earnings data on Thursday, July 31st. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.03). The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.07 million.

Institutional Trading of Envoy Medical

A number of institutional investors have recently modified their holdings of COCH. Arcus Capital Partners LLC bought a new stake in shares of Envoy Medical in the first quarter valued at about $244,000. Focus Partners Wealth bought a new stake in shares of Envoy Medical in the first quarter valued at about $276,000. Finally, NorthRock Partners LLC bought a new stake in shares of Envoy Medical in the second quarter valued at about $14,612,000. 8.59% of the stock is currently owned by institutional investors.

Envoy Medical Company Profile

Envoy Medical, Inc, a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc in September 2023.